Recurrent Aggressive Angiomyxoma That Responded to the Gonadotropin-Releasing Hormone (GnRH) Antagonist Relugolix
Abstract
Aggressive angiomyxoma (AAM) is a rare benign mesenchymal tumor occurring in the vulva, vagina, and pelvis; however, it is difficult to treat because it often recurs locally. Since AAM expresses the estrogen receptor (ER) and progesterone receptor (PgR), various hormone therapies have been reportedly effective. Regardless, the efficacy of gonadotropin-releasing hormone (GnRH) antagonists has not yet been reported. We encountered a case of relapsed AAM in which the GnRH antagonist relugolix was highly effective. Although the patient initially underwent surgical resection for the AAM, recurrence occurred 11 months postoperatively. Since the immunohistochemical expression of ER and PgR was positive, relugolix (40 mg/day) was orally administered daily for six months, resulting in significant tumor regression (8.7 cm to 4.6 cm). This is the first report of successful GnRH antagonist treatment for AAM. Although AAM may be difficult to treat, GnRH antagonists are promising candidates for hormone therapy.
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer
- What are the causes of late-life depression?
- Identification of SOX3 as an XX male sex reversal gene in mice and humans
- Retrospective study of concussive convulsions in elite Australian rules and rugby league footballers: phenomenology, aetiology, and outcome
- Uveal melanomas presenting during pregnancy and the investigation of oestrogen receptors in melanomas
- Metabolic and pathologic profiles of human LSS deficiency recapitulated in mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.